Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Purchased by ProShare Advisors LLC

ProShare Advisors LLC raised its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 4.4% during the 2nd quarter, Holdings Channel.com reports. The firm owned 2,959 shares of the medical research company’s stock after acquiring an additional 126 shares during the quarter. ProShare Advisors LLC’s holdings in Bio-Rad Laboratories were worth $808,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Capital Advisors Ltd. LLC grew its holdings in Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after buying an additional 62 shares in the last quarter. Sound Income Strategies LLC acquired a new position in Bio-Rad Laboratories during the 1st quarter worth $38,000. EntryPoint Capital LLC bought a new position in shares of Bio-Rad Laboratories in the first quarter worth $51,000. Parallel Advisors LLC increased its holdings in shares of Bio-Rad Laboratories by 36.8% during the fourth quarter. Parallel Advisors LLC now owns 171 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 46 shares during the period. Finally, Headlands Technologies LLC bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at about $51,000. Institutional investors own 65.24% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on BIO shares. Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 target price on the stock. StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Citigroup upped their target price on Bio-Rad Laboratories from $300.00 to $350.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $401.00 price target on shares of Bio-Rad Laboratories in a research note on Friday, August 16th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $315.00 price objective (down previously from $440.00) on shares of Bio-Rad Laboratories in a report on Monday, June 3rd. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Bio-Rad Laboratories has a consensus rating of “Hold” and a consensus price target of $358.20.

Bio-Rad Laboratories Trading Down 0.1 %

Shares of NYSE:BIO opened at $331.77 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 6.28. The stock has a market capitalization of $9.46 billion, a price-to-earnings ratio of -32.02 and a beta of 0.95. Bio-Rad Laboratories, Inc. has a 1-year low of $261.59 and a 1-year high of $366.30. The company has a 50 day moving average price of $325.80 and a 200 day moving average price of $307.23.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, August 1st. The medical research company reported $3.11 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.99. The business had revenue of $638.50 million during the quarter, compared to analyst estimates of $645.79 million. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.73%. The company’s revenue was down 6.3% compared to the same quarter last year. During the same period last year, the company posted $3.00 EPS. On average, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.31 EPS for the current fiscal year.

Insider Activity at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the transaction, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now directly owns 7,559 shares of the company’s stock, valued at $2,494,016.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP James Barry sold 623 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the sale, the executive vice president now owns 147 shares of the company’s stock, valued at $48,582.03. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by corporate insiders.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.